Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
eyeforpharma Logo

8th Annual eyeforpharma Value Summit 2018 November 7 - 8th, 2018|Philadelphia, US

The industry changing agenda

07:30 - 09:00
REGISTRATION, EXHIBITION & WELCOME COFFEE
08:55 - 09:00
Chair opening remarks

PAREXEL Camie Britton VP, Medical and Scientific Services PAREXEL

09:00 - 09:45
Panel: The future of pharma requires a value shift
  • Change starts within: how to move towards investing in value beyond short-term wins
  • Why pharma must take the lead to build bridges across the healthcare ecosystem
  • How pharma can help stakeholders align to reduce costs and improve patient value

Moderator: Aetion Scott Musial Head of Client Delivery Aetion

Boehringer Ingelheim Anjan Chatterjee VP, Global Head RWE - COE, Epidemiology and Big Data Boehringer Ingelheim

GSK Martin Marciniak VP, US Medical Affairs, Customer Engagement, Value, Evidence and Outcomes GSK

EMD Serono Zhen Su SVP, Chief Medical Officer, North America EMD Serono

09:45 - 10:05
Advance the use of RWE – an industry progress health check and next steps
  • Inventories 2018 state of RWE uses in clinical research
  • Examine operational hurdles for bleeding-edge applications of RWD in RWE research paradigms
  • Explore innovations that can support resolution of unsolved challenges (such as patient consent management, adherence to privacy/data storage regulation, interoperability, data sharing incentives, statistical approaches, etc.) that aligns with current regulatory and healthcare delivery landscape
  • Discuss essential RWD enablers that delivery teams must master in order to successfully innovate

PAREXEL Camie Britton Vice President, Medical and Scientific Services PAREXEL

10:05 - 10:25
Prove the value of digital medicine – the case of Abilify MyCite
  • Learn how to overcome challenges commercializing digital technologies
  • Understand payer needs for creating long-term, outcomes-based agreements for digital products
  • The next steps in scaling digital products to revolutionize healthcare delivery and understanding

Otsuka John Bardi VP Public Affairs & Digital Health Business Development Otsuka

10:25 - 11:00
EXHIBITION & NETWORKING COFFEE BREAK
11:00 - 11:25
FDA real-world evidence vision and policy
  • Implementation of the 21st Century Cures Act
  • FDA real-world demonstration projects – Exploring the future

FDA Khair ElZarrad Deputy Director, Office of Medical Policy FDA

11:25 - 11:55
Fireside Chat: Use data, analytics, and services to assess and monitor the value of healthcare products
  • Establishing transparency in data sources and methods used to determine product value
  • Fostering trust between payer/manufacturers as partners in contracting
  • Building a scalable approach to value-based contracting for long-term benefits

IBM Watson Health Denise Meade Director of Product Management IBM Watson Health

Pfizer Sachin Kamal Vice President and Innovation Center Head, Global Health & Value Pfizer

11:55 - 12:15
Integrate Real World Evidence Data To Promote Success In Value Based Partnerships
  • Strategies to assists in finding a balance to allow providers and manufactures to find a balance in sharing data control in order to comply with the legal standard

Pfizer Christopher Boone Vice President, Head of Real World Data and Analytics Center of Excellence Pfizer

12:15 - 1:15
PHARMA ONLY Workshop: Real-World Evidence to Real-World Intelligence: Volume, Variety, Velocity!

To truly benefit from our investments in Real-World Data (RWD), we need robust and advanced analytics that can keep pace with the increasing volume, variety, and velocity of the data sources. However, for many organizations, this can be a challenge. 

You’re invited to join your peers to discuss RWD, RWE, and RWI. You’ll walk away from this interactive conversation armed with strategies to make more effective use of your RWE investment. In this workshop, you can expect to:

  • Discuss and prioritize challenges your organization faces generating RWI
  • Share best practices and discuss how RWD and RWI can address societal challenges, like the opioid epidemic
  • Explore opportunities for extracting intelligence from RWD, including ways to reduce the time it takes to yield actionable insights to support your organization’s goals

SAS Sherrine Eid Principal Industry Consultant SAS

SAS Robert Collins Manager SAS

1:15 - 2:00
EXHIBITION & NETWORKING LUNCH BREAK
2:00 - 2:45
Panel: Communicate and contract for value in an evolving legal landscape
  • Discuss recent FDA final guidance on use of Health Economic Information
  • Update on the status of existing and new safe harbors impacting value based contracting
  • Understand compliant use of dynamic data modeling and RWE when working with payers and providers
  • Best practices in contracting for use of digital health platforms and data when designing value-based offers

Moderator: Covington Rujul Desai Of Counsel Covington

AbbVie Brad Patrick Division Counsel AbbVie

Covington Michael Labson Partner Covington

Further panellist TBC

2:45 - 3:10
Case Study: How to Advance Real-World Evidence by Incorporating Patient-Generated Health Data
  • Discuss the value of patient-generated health data
  • Explore how companies are using patient-generated health data
  • Illustrate how patient-generated health data can support the shift to value-based care

Evidation Health Mikki Nasch Co-founder and Vice President of Business Development Evidation Health

Sanofi Anjali Trasy Global Head Patient Engagement Strategy Sanofi

3:10 - 3:30
Create a Multi-stakeholder and Integrated Blueprint for VBC: A Medical Affairs Perspective
  • Collaboratively define VBC driven endpoints with payers and strategize the burden of evidence
  • Integrate provider perspectives to drive VBC adoptions and support for evidence generation
  • Set patient at the center of VBC strategy and generate a payer-patient value chain

Acer Therapeutics Usman Iqbal Vice President, Medical Affairs Acer Therapeutics

3:30 - 4:10
EXHIBITION & NETWORKING COFFEE BREAK
4:10 - 4:35
Fireside chat: Are Employers the new gatekeepers to access?
  • Essential briefing on how employers view the changing access landscape
  • How do employers view value and where do they differ from payers?
  • Can pharma contract directly with employers? Is this the next frontier for value-based contracting?

National Alliance of Healthcare Purchaser Coalitions Michael Thompson President & CEO National Alliance of Healthcare Purchaser Coalitions

Bayer Reg Waldeck Market Access Strategy Leader Bayer

4:35 - 4:55
Find synergy between Product Development and Commercialization - the Biopharmaceutical Acceleration Model
  • How historically product development has largely been disengaged from commercialization
  • How in the current healthcare environment, health system stakeholders demand both clinical and real-world evidence to inform decisions regarding product use and reimbursement
  • Meet clinical, regulatory and commercial needs with using the Biopharmaceutical Acceleration Model approach for comprehensive evidence development

Syneos Health John McCormick Vice President, Client Engagement, Real World & Late Phase Syneos Health

4:55 - 5:35
Panel: The Roadmap to Scale VBC
  • What lessons can we learn from failure of previous attempts at VBC?
  • Case Study: How Aetna and Merck created their VBC for Januvia
  • Create incentives to align partners and scale the adoption of VBC

Moderator: National Pharmaceutical Council Dan Leonard President National Pharmaceutical Council

Aetna Harry Vargo Director of Value Based Contracting and Manufacturer Trade Relations Aetna

Merck David Hartenbaum Executive Director, Account Management Merck

5:35 - 7:30
EXHIBITION & NETWORKING DRINKS RECEPTION

Day 2

08:00 - 09:00
REGISTRATION, EXHIBITION & WELCOME COFFEE
08:55 - 09:00
Chair opening remarks

Otsuka John Bardi VP, Public Affairs & Digital Health Business Development Otsuka

09:05 - 09:50
Strategic Collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients
  • Investigate success factors for meaningful pharma provider systems engagement
  • Explore opportunities for implementation of VBC programs using population health
  • Discuss unique advantages of direct-to-system collaborations over traditional payer engagements
  • Learn how to leverage real-world evidence programs and risk-based contracting

Moderator: Pharmvivo Ulrich Neumann Founder Pharmvivo

Astellas Americas Shontelle Dodson SVP, Health Systems Astellas Americas

Pfizer Oncology Gergana Zlateva VP, Payer Insights and Access Pfizer Oncology

Sunovion Pharmaceutical Matt Portch Vice President, Managed Markets Sunovion Pharmaceutical

Regional Cancer Care Associates Terrill Jordan President & CEO Regional Cancer Care Associates

09:50 - 10:10
Pairing Real-World Data with treatment guidelines to identify and access underserved patient populations
  • Learn by example how you can use real-world data to find treatment-eligible patients at a local level to maximize your treated-patient conversion rates within the addressable population
  • Claims and EHR analysis linked to treatment guidelines and established standards of care to identify and size eligible patient populations
  • Identification of major patient “drop-out” points to understand where to focus your commercial activity
  • How variability in regional care delivery and patient disease burden impacts treatment pull-through opportunity

drg Adrienne Lovink Partner, Consulting DRG

10:10 - 10:30
Economic Evaluations and Value Frameworks: Leveraging the entire data spectrum to elucidate value
  • Analysis of the current state of value frameworks (US and Global)
  • Explore the limitations and key gaps of current economic evaluations
  • Use the data spectrum to fully give value to innovation: RCTs, indirect evidence, prospective, real world, and modelling

Janssen Sean McElligott Director, Market Access, Scientific and External Strategy Janssen

10:30 - 11:00
EXHIBITION & NETWORKING COFFEE BREAK
11:00 - 11:45
Opportunities and Challenges in Accessing and Using Data
  • Old and New Approaches to Data Access and Partnership.
  • The Increasingly Complex World of Data Privacy
  • Technology Advances and Gaps, including use of AI, NLP and Patient-generated Data
  • Extending the Use of Real World Data

Moderator: OM1 Rich Gliklich CEO OM1

Boehringer Ingelheim Anjan Chatterjee VP, Global Head RWE - COE, Epidemiology and Big Data Boehringer Ingelheim

Celgene Kimberly Wilson Director Data Management (Information, Knowledge Utilization - iKU) Celgene

Vertex Pharmaceuticals Vaidyanathan Ganapathy Director, Global Real World Evidence COE Vertex

Janssen Sean McElligott Director, Market Access, Scientific and External Strategy Janssen

11:45 - 12:05
How evolving your data lake into a data hub can turn real world data into evidence faster
  • Using AI and machine learning to accelerate RWE requires highly curated, semantically searchable data
  • Why the typical data lake deployed 3 years ago isn’t up to the task of operationalizing RWE insights
  • How smarter and more flexible Operational Data Hub (ODH) can accelerate innovation and development of better RWE

mark_logic Imran Chaudhri Chief Architect for Healthcare and Life Sciences MarkLogic

12:05 - 12:55
ROUNDTABLE DEBATES
  1. Real-time patient insights: explore how to overcome issues with data quality and trust from the new era of digital devices
  2. Agree on outcomes: discuss experience and best practices on effective communication with payers and agreeing on desired outcomes
  3. Social media as a source of RWE: discuss how emerging technologies such as Natural Language Processing (NLP) are being used to find new patient insights
  4. The pragmatic solution: explore different approaches to defining the right question for pragmatic studies
  5. Real-world patients: how can pharma engage with patients regarding ownership and data use?
  6. The use of RWE in clinical trials: debate how to best incorporate big data insights into the development process, keeping high data relevance and quality
  7. Europe’s GDPR tremor: is a shift in US privacy regulation around the corner? Discuss the impact new EU regulations are already having and how they might alter the US system
  8. Discuss experiences in achieving value-based contracts: where are they most appropriate? Most likely to succeed? Differences in payer and pharma requirements?

American Living Organ Donor Fund Michael Mittelman Executive Director American Living Organ Donor Fund

Cutaneous Lymphoma Foundation Susan Thornton CEO Cutaneous Lymphoma Foundation

GSK Rafael Alfonso Senior Director, Value Evidence and Outcomes, Scientific Lead – Americas, GSK

Bayer Stephanie Chen Market Access Bayer

DRG Keshia Maughn Director, Data Science Methodology DRG

1:00 - 2:00
EXHIBITION & NETWORKING LUNCH BREAK
2:00 - 2:20
Case study: Accelerate clinical development leveraging real-world data
  • Inform phase 3 trial design by enabling clinical colleagues to define endpoints and inclusion criteria more accurately
  • See how Lilly adapted traditional FDA submission standards to incorporate new levels of patient/population understanding from RWE sources

Eli Lilly Diana Stefani-Hunyady Global Senior Director, IL-23 Medical Affairs Launch Lead Eli Lilly

2:20 - 2:40
Accelerate therapeutic development with blockchain technology – the case for a drug development meritocracy
  • Discuss the impact of blockchain on data ownership and the breaking down of data silos
  • Explore use case examples of blockchain technology in patient registries and genomic matching
  • Build industry trust in blockchain through the reputation systems: KYC – Know Your Customer, Collaborator, Clinician

Mitsubishi Bryan Hill Medical Science Director Mitsubishi

2:40 - 3:00
Case Study: How Discover Diabetes is setting new standards for global epidemiology
  • The story behind AstraZeneca's platform to enrol patients from >35 countries in a global study of diabetes treatment and outcomes
  • Identification of the drivers of diabetes care across the world
  • How to pull through best practices for multi-country real-world studies

AstraZeneca Eric Wittbrodt Director, Epidemiology AstraZeneca

3:00 - 3:20
Are you taking advantage of the RWD value opportunity in healthcare?
  • Essential takeaway exploring a range of different use case examples for RWD application
  • Moving forward and finding the path – key considerations for the next steps on fully unlocking RWD

Seqirus Shanthy Krishnarajah Global Head of Market Access & Reimbursement Strategy Seqirus

3:20 - END
Coffee available to stay or go
07:30 - 09:00
REGISTRATION, EXHIBITION & WELCOME COFFEE
08:55 - 09:00
Chair opening remarks

PAREXEL Camie Britton VP, Medical and Scientific Services PAREXEL

09:00 - 09:45
Panel: The future of pharma requires a value shift
  • Change starts within: how to move towards investing in value beyond short-term wins
  • Why pharma must take the lead to build bridges across the healthcare ecosystem
  • How pharma can help stakeholders align to reduce costs and improve patient value

Moderator: Aetion Scott Musial Head of Client Delivery Aetion

Boehringer Ingelheim Anjan Chatterjee VP, Global Head RWE - COE, Epidemiology and Big Data Boehringer Ingelheim

GSK Martin Marciniak VP, US Medical Affairs, Customer Engagement, Value, Evidence and Outcomes GSK

EMD Serono Zhen Su SVP, Chief Medical Officer, North America EMD Serono

09:45 - 10:05
Advance the use of RWE – an industry progress health check and next steps
  • Inventories 2018 state of RWE uses in clinical research
  • Examine operational hurdles for bleeding-edge applications of RWD in RWE research paradigms
  • Explore innovations that can support resolution of unsolved challenges (such as patient consent management, adherence to privacy/data storage regulation, interoperability, data sharing incentives, statistical approaches, etc.) that aligns with current regulatory and healthcare delivery landscape
  • Discuss essential RWD enablers that delivery teams must master in order to successfully innovate

PAREXEL Camie Britton Vice President, Medical and Scientific Services PAREXEL

10:05 - 10:25
Prove the value of digital medicine – the case of Abilify MyCite
  • Learn how to overcome challenges commercializing digital technologies
  • Understand payer needs for creating long-term, outcomes-based agreements for digital products
  • The next steps in scaling digital products to revolutionize healthcare delivery and understanding

Otsuka John Bardi VP Public Affairs & Digital Health Business Development Otsuka

10:25 - 11:00
EXHIBITION & NETWORKING COFFEE BREAK
11:00 - 11:25
FDA real-world evidence vision and policy
  • Implementation of the 21st Century Cures Act
  • FDA real-world demonstration projects – Exploring the future

FDA Khair ElZarrad Deputy Director, Office of Medical Policy FDA

11:25 - 11:55
Fireside Chat: Use data, analytics, and services to assess and monitor the value of healthcare products
  • Establishing transparency in data sources and methods used to determine product value
  • Fostering trust between payer/manufacturers as partners in contracting
  • Building a scalable approach to value-based contracting for long-term benefits

IBM Watson Health Denise Meade Director of Product Management IBM Watson Health

Pfizer Sachin Kamal Vice President and Innovation Center Head, Global Health & Value Pfizer

11:55 - 12:15
Integrate Real World Evidence Data To Promote Success In Value Based Partnerships
  • Strategies to assists in finding a balance to allow providers and manufactures to find a balance in sharing data control in order to comply with the legal standard

Pfizer Christopher Boone Vice President, Head of Real World Data and Analytics Center of Excellence Pfizer

12:15 - 1:15
PHARMA ONLY Workshop: Real-World Evidence to Real-World Intelligence: Volume, Variety, Velocity!

To truly benefit from our investments in Real-World Data (RWD), we need robust and advanced analytics that can keep pace with the increasing volume, variety, and velocity of the data sources. However, for many organizations, this can be a challenge. 

You’re invited to join your peers to discuss RWD, RWE, and RWI. You’ll walk away from this interactive conversation armed with strategies to make more effective use of your RWE investment. In this workshop, you can expect to:

  • Discuss and prioritize challenges your organization faces generating RWI
  • Share best practices and discuss how RWD and RWI can address societal challenges, like the opioid epidemic
  • Explore opportunities for extracting intelligence from RWD, including ways to reduce the time it takes to yield actionable insights to support your organization’s goals

SAS Sherrine Eid Principal Industry Consultant SAS

SAS Robert Collins Manager SAS

1:15 - 2:00
EXHIBITION & NETWORKING LUNCH BREAK
2:00 - 2:45
Panel: Communicate and contract for value in an evolving legal landscape
  • Discuss recent FDA final guidance on use of Health Economic Information
  • Update on the status of existing and new safe harbors impacting value based contracting
  • Understand compliant use of dynamic data modeling and RWE when working with payers and providers
  • Best practices in contracting for use of digital health platforms and data when designing value-based offers

Moderator: Covington Rujul Desai Of Counsel Covington

AbbVie Brad Patrick Division Counsel AbbVie

Covington Michael Labson Partner Covington

Further panellist TBC

2:45 - 3:10
Case Study: How to Advance Real-World Evidence by Incorporating Patient-Generated Health Data
  • Discuss the value of patient-generated health data
  • Explore how companies are using patient-generated health data
  • Illustrate how patient-generated health data can support the shift to value-based care

Evidation Health Mikki Nasch Co-founder and Vice President of Business Development Evidation Health

Sanofi Anjali Trasy Global Head Patient Engagement Strategy Sanofi

3:10 - 3:30
Create a Multi-stakeholder and Integrated Blueprint for VBC: A Medical Affairs Perspective
  • Collaboratively define VBC driven endpoints with payers and strategize the burden of evidence
  • Integrate provider perspectives to drive VBC adoptions and support for evidence generation
  • Set patient at the center of VBC strategy and generate a payer-patient value chain

Acer Therapeutics Usman Iqbal Vice President, Medical Affairs Acer Therapeutics

3:30 - 4:10
EXHIBITION & NETWORKING COFFEE BREAK
4:10 - 4:35
Fireside chat: Are Employers the new gatekeepers to access?
  • Essential briefing on how employers view the changing access landscape
  • How do employers view value and where do they differ from payers?
  • Can pharma contract directly with employers? Is this the next frontier for value-based contracting?

National Alliance of Healthcare Purchaser Coalitions Michael Thompson President & CEO National Alliance of Healthcare Purchaser Coalitions

Bayer Reg Waldeck Market Access Strategy Leader Bayer

4:35 - 4:55
Find synergy between Product Development and Commercialization - the Biopharmaceutical Acceleration Model
  • How historically product development has largely been disengaged from commercialization
  • How in the current healthcare environment, health system stakeholders demand both clinical and real-world evidence to inform decisions regarding product use and reimbursement
  • Meet clinical, regulatory and commercial needs with using the Biopharmaceutical Acceleration Model approach for comprehensive evidence development

Syneos Health John McCormick Vice President, Client Engagement, Real World & Late Phase Syneos Health

4:55 - 5:35
Panel: The Roadmap to Scale VBC
  • What lessons can we learn from failure of previous attempts at VBC?
  • Case Study: How Aetna and Merck created their VBC for Januvia
  • Create incentives to align partners and scale the adoption of VBC

Moderator: National Pharmaceutical Council Dan Leonard President National Pharmaceutical Council

Aetna Harry Vargo Director of Value Based Contracting and Manufacturer Trade Relations Aetna

Merck David Hartenbaum Executive Director, Account Management Merck

5:35 - 7:30
EXHIBITION & NETWORKING DRINKS RECEPTION

Day 2

08:00 - 09:00
REGISTRATION, EXHIBITION & WELCOME COFFEE
08:55 - 09:00
Chair opening remarks

Otsuka John Bardi VP, Public Affairs & Digital Health Business Development Otsuka

09:05 - 09:50
Strategic Collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients
  • Investigate success factors for meaningful pharma provider systems engagement
  • Explore opportunities for implementation of VBC programs using population health
  • Discuss unique advantages of direct-to-system collaborations over traditional payer engagements
  • Learn how to leverage real-world evidence programs and risk-based contracting

Moderator: Pharmvivo Ulrich Neumann Founder Pharmvivo

Astellas Americas Shontelle Dodson SVP, Health Systems Astellas Americas

Pfizer Oncology Gergana Zlateva VP, Payer Insights and Access Pfizer Oncology

Sunovion Pharmaceutical Matt Portch Vice President, Managed Markets Sunovion Pharmaceutical

Regional Cancer Care Associates Terrill Jordan President & CEO Regional Cancer Care Associates

09:50 - 10:10
Pairing Real-World Data with treatment guidelines to identify and access underserved patient populations
  • Learn by example how you can use real-world data to find treatment-eligible patients at a local level to maximize your treated-patient conversion rates within the addressable population
  • Claims and EHR analysis linked to treatment guidelines and established standards of care to identify and size eligible patient populations
  • Identification of major patient “drop-out” points to understand where to focus your commercial activity
  • How variability in regional care delivery and patient disease burden impacts treatment pull-through opportunity

drg Adrienne Lovink Partner, Consulting DRG

10:10 - 10:30
Economic Evaluations and Value Frameworks: Leveraging the entire data spectrum to elucidate value
  • Analysis of the current state of value frameworks (US and Global)
  • Explore the limitations and key gaps of current economic evaluations
  • Use the data spectrum to fully give value to innovation: RCTs, indirect evidence, prospective, real world, and modelling

Janssen Sean McElligott Director, Market Access, Scientific and External Strategy Janssen

10:30 - 11:00
EXHIBITION & NETWORKING COFFEE BREAK
11:00 - 11:45
Opportunities and Challenges in Accessing and Using Data
  • Old and New Approaches to Data Access and Partnership.
  • The Increasingly Complex World of Data Privacy
  • Technology Advances and Gaps, including use of AI, NLP and Patient-generated Data
  • Extending the Use of Real World Data

Moderator: OM1 Rich Gliklich CEO OM1

Boehringer Ingelheim Anjan Chatterjee VP, Global Head RWE - COE, Epidemiology and Big Data Boehringer Ingelheim

Celgene Kimberly Wilson Director Data Management (Information, Knowledge Utilization - iKU) Celgene

Vertex Pharmaceuticals Vaidyanathan Ganapathy Director, Global Real World Evidence COE Vertex

Janssen Sean McElligott Director, Market Access, Scientific and External Strategy Janssen

11:45 - 12:05
How evolving your data lake into a data hub can turn real world data into evidence faster
  • Using AI and machine learning to accelerate RWE requires highly curated, semantically searchable data
  • Why the typical data lake deployed 3 years ago isn’t up to the task of operationalizing RWE insights
  • How smarter and more flexible Operational Data Hub (ODH) can accelerate innovation and development of better RWE

mark_logic Imran Chaudhri Chief Architect for Healthcare and Life Sciences MarkLogic

12:05 - 12:55
ROUNDTABLE DEBATES
  1. Real-time patient insights: explore how to overcome issues with data quality and trust from the new era of digital devices
  2. Agree on outcomes: discuss experience and best practices on effective communication with payers and agreeing on desired outcomes
  3. Social media as a source of RWE: discuss how emerging technologies such as Natural Language Processing (NLP) are being used to find new patient insights
  4. The pragmatic solution: explore different approaches to defining the right question for pragmatic studies
  5. Real-world patients: how can pharma engage with patients regarding ownership and data use?
  6. The use of RWE in clinical trials: debate how to best incorporate big data insights into the development process, keeping high data relevance and quality
  7. Europe’s GDPR tremor: is a shift in US privacy regulation around the corner? Discuss the impact new EU regulations are already having and how they might alter the US system
  8. Discuss experiences in achieving value-based contracts: where are they most appropriate? Most likely to succeed? Differences in payer and pharma requirements?

American Living Organ Donor Fund Michael Mittelman Executive Director American Living Organ Donor Fund

Cutaneous Lymphoma Foundation Susan Thornton CEO Cutaneous Lymphoma Foundation

GSK Rafael Alfonso Senior Director, Value Evidence and Outcomes, Scientific Lead – Americas, GSK

Bayer Stephanie Chen Market Access Bayer

DRG Keshia Maughn Director, Data Science Methodology DRG

1:00 - 2:00
EXHIBITION & NETWORKING LUNCH BREAK
2:00 - 2:20
Case study: Accelerate clinical development leveraging real-world data
  • Inform phase 3 trial design by enabling clinical colleagues to define endpoints and inclusion criteria more accurately
  • See how Lilly adapted traditional FDA submission standards to incorporate new levels of patient/population understanding from RWE sources

Eli Lilly Diana Stefani-Hunyady Global Senior Director, IL-23 Medical Affairs Launch Lead Eli Lilly

2:20 - 2:40
Accelerate therapeutic development with blockchain technology – the case for a drug development meritocracy
  • Discuss the impact of blockchain on data ownership and the breaking down of data silos
  • Explore use case examples of blockchain technology in patient registries and genomic matching
  • Build industry trust in blockchain through the reputation systems: KYC – Know Your Customer, Collaborator, Clinician

Mitsubishi Bryan Hill Medical Science Director Mitsubishi

2:40 - 3:00
Case Study: How Discover Diabetes is setting new standards for global epidemiology
  • The story behind AstraZeneca's platform to enrol patients from >35 countries in a global study of diabetes treatment and outcomes
  • Identification of the drivers of diabetes care across the world
  • How to pull through best practices for multi-country real-world studies

AstraZeneca Eric Wittbrodt Director, Epidemiology AstraZeneca

3:00 - 3:20
Are you taking advantage of the RWD value opportunity in healthcare?
  • Essential takeaway exploring a range of different use case examples for RWD application
  • Moving forward and finding the path – key considerations for the next steps on fully unlocking RWD

Seqirus Shanthy Krishnarajah Global Head of Market Access & Reimbursement Strategy Seqirus

3:20 - END
Coffee available to stay or go

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription